SK Biopharmaceuticals Co Ltd
KRX:326030
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
75 700
125 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
Total Current Liabilities
SK Biopharmaceuticals Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Total Current Liabilities
₩241.6B
|
CAGR 3-Years
51%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Total Current Liabilities
₩570.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Total Current Liabilities
₩426.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Total Current Liabilities
₩623.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Total Current Liabilities
₩58.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Total Current Liabilities
₩237.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
SK Biopharmaceuticals Co Ltd
Glance View
SK Biopharmaceuticals Co., Ltd., a prominent player in the global biopharmaceutical industry, emerged as a distinctive entity out of one of South Korea's largest conglomerates, the SK Group. This pharmaceutical jewel draws its strength from innovation in the neurology and oncology sectors, fields brimming with both challenge and opportunity. At its core, SK Biopharmaceuticals is dedicated to the research, development, and commercialization of novel medications, with a significant focus on disorders impacting the central nervous system. Their pipeline and commercial activities revolve around cutting-edge therapies, such as the epilepsy drug Cenobamate, which has gained a foothold in both the U.S. and European markets. This drug, marketed under different names like Xcopri in the U.S., is a testament to the company's ability to leverage robust R&D capabilities into profitable products. Revenue generation for SK Biopharmaceuticals is predominantly driven by the sales of their innovative therapeutic solutions, as well as strategic collaborations with a network of global partners. They engage in a lifecycle approach where they not only develop and launch their own drugs but also license out their intellectual property, enhancing revenue streams through royalties and milestone payments. This hybrid model of sales and strategic partnerships showcases a deft mix of scientific prowess and commercial acumen, key to sustaining and propelling growth in a competitive market. Additionally, they continuously invest in research and alliances, aiming to expand their portfolio beyond existing successes, while targeting unmet medical needs that mirror their core strengths. This balanced approach positions SK Biopharmaceuticals not just as a standalone drugmaker, but as a dynamic player in shaping future therapies in their chosen niches.
See Also
What is SK Biopharmaceuticals Co Ltd's Total Current Liabilities?
Total Current Liabilities
241.6B
KRW
Based on the financial report for Dec 31, 2023, SK Biopharmaceuticals Co Ltd's Total Current Liabilities amounts to 241.6B KRW.
What is SK Biopharmaceuticals Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
51%
Over the last year, the Total Current Liabilities growth was 48%. The average annual Total Current Liabilities growth rates for SK Biopharmaceuticals Co Ltd have been 51% over the past three years , 51% over the past five years .
You don't have any saved screeners yet
